Cargando…
Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up
Nivolumab is an immune checkpoint inhibitor used to treat multiple solid-organ malignancies. While many of its immune-related adverse events are well established, nivolumab-induced sclerosing cholangitis remains poorly characterised, with no defined diagnostic criteria. Moreover, data regarding long...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484867/ https://www.ncbi.nlm.nih.gov/pubmed/32912846 http://dx.doi.org/10.1136/bmjgast-2020-000487 |